Skip to content

EndoVascular Rapair with Sac Embolization for the Prevention of Type II Endoleaks (the EVAR-SE Study)

EndoVascular Rapair with Sac Embolization for the Prevention of Type II Endoleaks (the EVAR-SE Study) - EVAR-SE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037952
Enrollment
100
Registered
2025-09-25
Start date
2022-12-13
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I71.4

Interventions

Group 1: Patients in the intervention group receive standard EVAR, in which a catheter is inserted into the aneurysm sac prior to stent graft implantation in order to perform coil embolization with at

Sponsors

Münchner Studienzentrum
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Infrarenal AAA =50 mm maximum diameter - Indication for EVAR within IFU of company - Presence of one or both high risk criteria on CT-A: 1. =5 patent efferent vessels (inferior mesenteric and/or lumbar artery, and/or median sacral artery) 2. <40% thrombus at largest AAA diameter

Exclusion criteria

Exclusion criteria: - Ruptured AAA - Fenestrated/branched EVAR - Pregnancy - Concomitant iliac artery aneurysm - Non-ability to adhere to the FU protocol - Lack of consent

Design outcomes

Primary

MeasureTime frame
Type II Endoleak at 12 months after procedure

Secondary

MeasureTime frame
- T2EL proportions at time points 2-4 days, 30 days and 6 months after EVAR treatment, as measured by CEUS and/or CT-A - Rates of any re-intervention (for endoleaks, occlusions, graft infection, graft migration) - Occurrence of any EL Type I or III - Changes of AAA diameter and volume as measured by CT-A in comparison to initial CT-A scan at V0 - Rate of AAA rupture 12 months after EVAR treatment - Mortality (aneurysm-related/not aneurysm related) 12 months after EVAR treatment - Change in quality of life assessed by SF-36 from baseline to 12 months after EVAR treatment

Countries

Germany

Contacts

Public ContactWissenschaftssekretariat Studienkoordination

Klinik und Poliklinik für Vaskuläre und Endovaskuläre Chirurgie TUM Klinikum Rechts der Isar

Wissenschaftssekretariat_GES@mri.tum.de+49 89 4140 9244

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026